Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Weight-loss drug firm becomes Europe’s most valuable

by September 6, 2023
September 6, 2023
Weight-loss drug firm becomes Europe’s most valuable

The maker of weight-loss drug Wegovy has become Europe’s most valuable firm, dethroning the French luxury conglomerate LVMH.

Shares rose after the Danish pharmaceutical giant, Novo Nordisk, launched the popular drug in the UK.

At the close of trading on Monday, the firm had a stock market valuation of $428bn (£339bn).

The drug is now available on the National Health Service in the UK and also on the private market.

Wegovy is an obesity treatment that is taken once a week which tricks people into thinking that they are already full, so they end up eating less and losing weight.

Famous personalities such as Elon Musk are among the reported users of the drug, which has captivated Hollywood and the public more widely since it was approved by regulators in the US in 2021.

Wegovy and Ozempic – a diabetes treatment with similar effects – have been described as “miracle” drugs.

But experts warn the jabs are not a quick fix nor a substitute for a healthy diet and exercise.

In trials, users often put weight back on after stopping treatment.

There has been a global shortage of the jabs so only limited stock arrived for the NHS in the UK on Monday.

The company said it would continue to restrict global supplies as it works to ramp up manufacturing.

Sophie Lund-Yates, lead equity analyst at Hargreaves Lansdown, said that the firm had been “genuinely surprised” by the uptake and said it had been “a victim of its own success”.

“It’s not common that you see a pharmaceutical company so entrenched in popular culture but there are people saying that we need to take a step back and ensure it is being used appropriately and responsibly. Of course, with a lot of fanfare for a drug, you are risking a lot of blowback in the future,” she said.

In the UK, NHS guidelines say patients can only access Wegovy, which contains the drug semaglutide, if they are significantly overweight and have weight-related health problems.

According to the Organisation for Economic Co-operation and Development (OECD), nearly one in three adults are obese in the UK, which is the highest level in Europe.

Last month, a new trial showed Wegovy has also been proven to reduce the risk of a stroke or heart attack.

While the findings still have to be fully reviewed, experts agreed the results were potentially significant.

Read more:
Weight-loss drug firm becomes Europe’s most valuable

0
FacebookTwitterGoogle +Pinterest
previous post
Britain’s school concrete crisis could cost over £150M
next post
Government proposes changes to disability and illness benefits

You may also like

Formula One stars team up to allow public...

November 20, 2023

Extra cladding tax will jeopardise 1.5 million homes...

March 14, 2025

Appetite for UK bonds grows after mini-budget led...

November 22, 2022

Ukrainian еngineer Andrii Nikulin leads industrial transformation with...

July 18, 2025

Surrey runs out of state school places for...

December 13, 2024

Gresham House Ventures backs Penfold with £3.9m to...

May 22, 2025

Calls mount for Neil Woodford to be stripped...

August 5, 2025

Asda consults on cutting pay for 7,000 workers

May 19, 2023

Investment app Gather collapses after failing to repay...

August 12, 2024

UK disposable incomes to fall by 3.8% in...

December 30, 2022

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Rutherford v. United States Brief: Defending the First Step Act

      August 15, 2025
    • Hawley opens probe into Meta after reports of AI romantic exchanges with minors

      August 15, 2025
    • Friday Feature: Braveheart Christian Academy

      August 15, 2025
    • From admiration to Alaska: A timeline of Trump and Putin’s high-stakes encounters

      August 15, 2025
    • Schumer claims Trump admin withholding Epstein files, threatens to sue

      August 15, 2025
    • UK prices for Mounjaro weight-loss jab to rise by up to 170% after Trump pressure on drugmakers

      August 15, 2025

    Categories

    • Business (8,796)
    • Investing (2,217)
    • Politics (16,392)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved